Compare · FMS vs MCTA
FMS vs MCTA
Side-by-side comparison of Fresenius Medical Care AG (FMS) and Charming Medical Limited (MCTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FMS and MCTA operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- FMS carries a market cap of $12.31B.
- FMS has been more active in the news (8 items in the past 4 weeks vs 5 for MCTA).
- FMS has more recent analyst coverage (25 ratings vs 0 for MCTA).
- Company
- Fresenius Medical Care AG
- Charming Medical Limited
- Price
- -
- -
- Market cap
- $12.31B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 8
- 5
- Recent ratings
- 25
- 0
Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Latest FMS
- Amendment: SEC Form SCHEDULE 13D/A filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical downgraded by Barclays
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care reports third quarter 2026 performance partially offsetting headwinds and narrowing full year outlook
- Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™
- Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026
- SEC Form 6-K filed by Fresenius Medical Care AG
- Shervin J. Korangy appointed CEO of Fresenius Medical Care to lead the next phase of strategic development and long-term profitable growth
Latest MCTA
- SEC Form 6-K filed by Charming Medical Limited
- Charming Medical Limited Announces Nasdaq Delisting Determination and Suspension of Trading
- SEC Form 6-K filed by Charming Medical Limited
- Charming Medical Limited Announces Receipt of Nasdaq Delisting Determination Notice.
- Charming Medical Limited Notified of Anticipated Delisting from The Nasdaq Stock Market
- SEC Form 6-K filed by Charming Medical Limited
- SEC Form 20-F filed by Charming Medical Limited
- SEC Form 6-K filed by Charming Medical Limited
- SEC Form 6-K filed by Charming Medical Limited
- SEC Form 6-K filed by Charming Medical Limited